Programmed Cell Death-1 Inhibitor–Induced Type 1 Diabetes Mellitus

2018229 citationsReviewbronze Open Access

Authors

Katleen Janssens · University of Antwerp

Pol Specenier · Antwerp University Hospital

Ilse Weets · Center for Beta Cell Therapy in Diabetes

Christophe De Block · University of Antwerp

Abstract

Because the use of immunotherapy will increase, it is essential that all clinicians are aware of diabetic ketoacidosis as a rare and life-threatening side effect of immunotherapy. Blood glucose monitoring during anti-PD-1 therapy is necessary.

Topics & Keywords

Cancer Immunotherapy and Biomarkers Phagocytosis and Immune Regulation CAR-T cell therapy research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 103, Issue 9, pp. 3144-3154

DOI: 10.1210/jc.2018-00728

Field-Weighted Citation Impact: 8.32